Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/15404
The NO signalling pathway in aortic aneurysm and dissection.
Br J Pharmacol. 2022 Apr;179(7):1287-1303
Recent studies have shown that NO is a central mediator in diseases associated with thoracic aortic aneurysm, such as Marfan syndrome. The progressive dilation of the aorta in thoracic aortic aneurysm ultimately leads to aortic dissection. Unfortunately, current medical treatments have neither halt aortic enlargement nor prevented rupture, leaving surgical repair as the only effective treatment. There is therefore a pressing need for effective therapies to delay or even avoid the need for surgical repair in thoracic aortic aneurysm patients. Here, we summarize the mechanisms through which NO signalling dysregulation causes thoracic aortic aneurysm, particularly in Marfan syndrome. We discuss recent advances based on the identification of new Marfan syndrome mediators related to pathway overactivation that represent potential disease biomarkers. Likewise, we propose iNOS, sGC and PRKG1, whose pharmacological inhibition reverses aortopathy in Marfan syndrome mice, as targets for therapeutic intervention in thoracic aortic aneurysm and are candidates for clinical trials.
Aortic Dissection | Aortic Aneurysm | Aortic Aneurysm, Thoracic | Marfan Syndrome | Animals | Aorta | Cyclic GMP-Dependent Protein Kinase Type I | Humans | Mice
Files in this item
- The NO signalling pathway in ...